MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
REGN Regeneron Pharmaceuticals
- 701.850
- -6.400-0.90%
Close Dec 20 16:00 ET
- 706.330
- +4.480+0.64%
Post 20:01 ET
77.13BMarket Cap17.36P/E (TTM)
717.610High700.830Low1.89MVolume710.200Open708.250Pre Close1.33BTurnover1.79%Turnover Ratio20.19P/E (Static)109.89MShares1211.20052wk High2.63P/B73.98BFloat Cap693.00052wk Low--Dividend TTM105.40MShs Float1211.200Historical High--Div YieldTTM2.37%Amplitude4.610Historical Low704.467Avg Price1Lot Size
About Regeneron Pharmaceuticals Company
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Company Profile
SymbolREGN
Company NameRegeneron Pharmaceuticals
Listing DateApr 2, 1991
Issue Price22.00
Founded1988
CEODr. Leonard S. Schleifer,M.D.,PhD
MarketNASDAQ
Employees13450
Fiscal Year Ends12-31
Address777 Old Saw Mill River Road
CityTarrytown
ProvinceNew York
CountryUnited States of America
Zip Code10591-6707
Phone1-914-847-7000
Websitehttp://www.regeneron.com
Company Executives
- Name
- Position
- Salary
- Dr. Leonard S. Schleifer,M.D.,PhD
- Co-Chairman of the Board, Co-President and Chief Executive Officer
- 8.18M
- Christopher R. Fenimore
- Senior Vice President, Finance and Chief Financial Officer
- --
- Dr. George D. Yancopoulos,M.D.,PhD
- Co-Chairman of the Board, Co-President and Chief Scientific Officer
- 7.76M
- Daniel P. Van Plew
- Executive Vice President and General Manager, Industrial Operations and Product Supply
- 8.76M
- Dr. Neil Stahl,PhD
- Executive Vice President, Research and Development
- --
- Andrew J Murphy
- Executive Vice President, Research
- 8.43M
- Jason Pitofsky
- Vice President and Controller
- --
- Marion McCourt
- Executive Vice President, Commercial
- --
- Joseph J. Larosa
- Executive Vice President, General Counsel and Secretary
- --
- Kathryn Guarini, PhD
- Director
- 1.03M
- Dr. David P. Schenkein, M.D.
- Director
- 1.03M
- George L. Sing
- Independent Director
- 724.99K
- Arthur Frederick Ryan
- Independent Director
- 724.99K
- Dr. Bonnie L. Bassler, PhD
- Independent Director
- 709.99K
- Dr. Michael S. Brown, M.D.
- Independent Director
- 728.99K
- Dr. Joseph L. Goldstein,M.D.
- Independent Director
- 709.99K
- Dr. Craig B. Thompson,M.D.
- Independent Director
- 247.79K
- Christine A. Poon
- Lead Independent Director
- 748.01K
- Dr. N. Anthony Coles, M.D.
- Independent Director
- 704.99K
- Dr. Huda Y. Zoghbi, M.D.
- Independent Director
- 714.99K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
